Academic Outreach & Non-Profit Screening Market Trends 2014 Research & Survey Report Available at RnRMarketResearch.com

RnRMarketResearch.com adds a 2014 survey report on Academic Outreach & Non-Profit Screening market that summarizes trends and results of HTStec's 2nd industry-wide global web-based benchmarking survey carried out in January 2014.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dallas, Texas (PRWEB) February 01, 2014

The main objectives of “Academic Outreach & Non-Profit Screening Trends 2014” market study were to compile a report that comprehensively documents the current status, operational capabilities, interests, assay readouts, formats, funding, budgets, success criteria and future investments of academic and non-profit screening centers. All survey results were expressed as an average of all screening centers on the ‘summary’ pages. In addition, all the individual responses from each screening center to every question are presented in the ‘detail’ pages. 55 screening centers participated in the survey. Of these 93% (51 out of 55) provided comprehensive input. Screening centers were geographically split: 60% North America; 34% Europe; 4% Rest of World; and 2% Asia (excluding Japan). The majority (56%) of screening centers surveyed came from the USA.

Comprehensive Table of Contents and complete report available at http://www.rnrmarketresearch.com/academic-outreach-non-profit-screening-trends-2014-market-report.html.

As per the report “Academic Outreach & Non-Profit Screening Trends 2014” the median total value of the pharma collaborations with screening centers was $100K-$250K. The majority (75%) of all screening center pharma collaborations were translational (i.e. provided access to clinical resources or drug development etc.). The current status of the screening centers surveyed were medians of 8 years operation and 2 additional years of assured funding. The publicly declared spending by screening centers to date was a median of $2.5M-$5M. Screening centers 2014 annual capex budget allocation for screening instrumentation and robotics was a median of $50K-$100K. The biggest proportion of this budget will be spent on detection instrumentation. The 2014 global market estimate for capex spending at screening centers was around $46M per year. Screening centers 2014 annual budget allocation for reagents+consumables was a median of $100K-$250K. The biggest proportion of this budget was spent on plastic consumables and off-the-shelf commercial assay kits. The 2014 global market estimate for reagents+consumables spending at screening centers was around $29M per year.

The report, available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=146235 looked at the following aspects of academic outreach and non-profit screening as practiced today (2014) by the screening centers surveyed:

  •     Full name of the screening center, the organisation/institution to which the screening center is affiliated and its geographic location.
  •     Type of organisation/institution the screening center is affiliated with.
  •     The center’s focus; activities undertaken at the center.
  •     Aspects of the screening process the center supports.
  •     Details of the compound libraries used or available to the center.
  •     Application areas or disease focus of the center.
  •     Focus on certain therapeutic targets.
  •     Target classes the center is most experienced in screening.
  •     Screening capabilities in 2013 in terms of the number of therapeutic targets screened per year and the total number of wells (all targets) screened per year.
  •     Maximum throughput for certain assay types.
  •     Typical duration of a screening project; % of screens undertaken that were cell-based, biochemical or whole organism.
  •     Microplate formats used for the majority of assays undertaken.
  •     Most used final assay volume and maximum % DMSO.
  •     Assay readouts (detection modalities) supported in full HTS (screening) mode and used routinely for secondary screening/screening confirmation.
  •     Assay readouts most used in actual primary screens over the previous 12 months.
  •     Specific assay types centers have real screening experience of using.
  •     % of different cell types used in cellular screens.
  •     Use of assay-ready cryopreserved cells for screening.
  •     New screening tools or technologies or approaches centers have implemented in the past 3 years.
  •     How centers rate the level of sophistication of their screening facilities.
  •     Number of FTEs employed in center’s operations and makeup of each center’s team.
  •     Where center’s derive their funding.
  •     How hits are taken forward to the next phase along the drug discovery value chain.
  •     Details of pharma collaborations.
  •     Years operation, additional years of assured funding, and publically declared $ spent to date.
  •     2014 capex and reagents+consumables budgets, plus their breakdown into components purchased.
  •     Where the center is making the biggest investments for the future.
  •     How key shareholders/stakeholders judge a centres’ screening success.
  •     Key difficulties faced by the center.
  •     How the center rates certain statements/goals/criteria.
  •     Steps centers are taking to maintain sustainability of operations
  •     Each centers unique activities, capabilities or selling points.

Explore more reports on the Healthcare Market at http://www.rnrmarketresearch.com/reports/life-sciences/healthcare.

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.


Contact

Follow us on: Contact's Google Plus